ClinicalTrials.gg
Active, not recruitingNCT07685821Updated Jul 8, 2026

In Vivo Study to Evaluate Tissue Remodeling Via Fibroblast Stimulation Following a Single SofWave Treatment

An interventional study of Sofwave in Lax Skin and Improve Facial Wrinkles, sponsored by Sofwave Medical LTD. Active, not recruiting at 1 site in United States. Open to participants aged 35 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-08.

Sponsored by Sofwave Medical LTD · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 6 months after the study started (first participant enrolled Dec 2025, registered Jun 2026).
Phase
Not applicable
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
35 Years to 60 Years
Sex
All
01

Study summary

Open-label, non-randomized single-arm prospective, single-center, self-controlled clinical study.

Read the detailed description

Eligible subjects will arrive for a screening visit, and if will be found eligible and will provide signed ICF, during this visit a biopsy will be taken from the pre-auricular area.

At the second visit, a week after the screening visit, sutures from the biopsy (if present) will be removed, and subjects will receive a single treatment on the full face, neck, and submental area using the SofWave system with the Lift applicator.

Subjects will return to the clinic for a follow-up visit at one of the following timepoints (2 subjects per timepoint): 5 days, 4 weeks ± 2 days, 8 weeks ± 2 days, 12 weeks ± 4 days, or 24 weeks ± 4 days post-treatment. During this visit, an additional biopsy will be taken from the opposite pre-auricular side to that used at the screening visit.

All subjects will arrive for an additional visit, a week after the follow-up visit, for suture removal (if will exist).

02

Conditions studied

  • Lax Skin
  • Improve Facial Wrinkles

Keywords

  • wrinkles
  • Lax Skin
  • Neck
  • Submental
  • Lifting
03

In context

Lead sponsor

Sofwave Medical LTD is the lead sponsor of 14 studies on the registry; 3 are open to participants now.

Of its 8 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
35 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy female and male subjects between the ages 35-60
  2. Non-Smoker.
  3. Fitzpatrick skin type I-VI.
  4. Desire to lift facial lax skin, neck and/or submental and/or to lift the eyebrow area and/or improve facial wrinkles appearance.
  5. Willing to give .
  6. Able and willing to comply with all visits, treatments and evaluation schedules and requirements (including providing biopsies).
  7. Able to understand and provide written .
  8. Women of child-bearing age are required to be using a reliable method of at least 3 months prior to study enrollment.
  9. Subject agrees not to undergo any other facial cosmetic treatment for a period of 3 months following last SofWave treatment.
  10. Stable weight over the last 12 weeks and throughout the duration of the study.

Exclusion criteria

Exclusion Criteria:

  1. Pregnant or planning to become pregnant, having given birth less than 3 months ago, and/or breast feeding.
  2. Presence of any active systemic or local infections.
  3. Presence of active local skin disease that may alter wound healing.
  4. Severe solar elastosis.
  5. Currently a smoker or has a history of heavy smoking (25 cigarettes per day or more) in the past 10 years.
  6. History of chronic drug or alcohol abuse.
  7. Excessive subcutaneous fat on the cheeks.
  8. Significant scarring in the area to be treated.
  9. Severe or cystic facial acne, and/or Accutane use during past 6 months.
  10. Presence of a metal stent or implant in the facial area (dental implants and/or braces are not excluded).
  11. Inability to understand the protocol or to provide a signed .
  12. History of cosmetic treatments in the facial area to be treated, including facial skin-tightening procedure within the past 6 months; injectable (Botox or fillers) of any type within the past 6 months; ablative or non-ablative resurfacing/rejuvenation laser treatment or light treatment within the past 6 months, dermabrasion or deep facial peels within the past 12 months; facelift, blepharoplasty, or brow lift (including contour threads) within the past 12 months.
  13. Taking Isotretinoin or other oral retinoid within the past 6 months; taking anti- or anti-coagulant within the past 2 weeks.
  14. As per the investigator's discretion, any physical or mental condition which might make it unsafe for the subject to participate in this study.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (estimated)

Study arms

  • Experimental
    lax tissue

    Device: Sofwave

Interventions

  • DeviceSofwave

    The Sofwave System, comprised of an applicator and a console, generates high intensity, non-focused ultrasonic energy which can be delivered percutaneously to tissues. Pure Impact is an EMS module. This module is wirelessly connected to and controlled by the SofWave console. It functions independently from the existing ultrasound module. Pure Impact generates electrical impulses, which are delivered through electrodes on the skin in direct proximity to the muscles to be stimulated.

06

What researchers measure

Primary outcomes

  1. Evaluate the biological responses

    Evaluate the biological responses of tissue inflammation, proliferation and remodeling via fibroblast stimulation following SofWave single treatment. Tissue biological responses will be correlated with the patients' skin laxity and global aesthetic improvement.

    Time frame: up to 24 weeks

07

Study locations

1 site
  • Dermatology Cosmetic Laser Associates of La Jolla, Inc
    San Diego, California 92121, United States
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07685821
Responsible party
Sponsor
First posted
Jul 6, 2026
Start date
Dec 22, 2025
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Jul 8, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion